Co-epidemics can create a burden on healthcare systems in the affected areas. The world, at present, is facing the pandemic of coronavirus disease. Nonetheless, many areas worldwide suffer from endemics that are not of less danger than the current pandemic. We presented a case of a patient diagnosed with dengue fever and was also found to have coronavirus through nasal swab, but immunoglobulin M and G were undetectable. Our case brings to notice the alarming probability of two co-epidemics happening simultaneously. However, through the presented case, our theory is that the dengue virus may cause a false-positive detection of severe acute respiratory syndrome coronavirus 2.

The management of oncological malignancies has significantly improved over the last decades. In modern medicine, new concepts and trends have emerged paving the way for the era of personalized and evidence-based strategies adapted to the patients’ prognostic variables and requirements. Several challenges do exist that are encountered during the management, including the difficulty to assess chemotherapy response with certainty. Having known that neoadjuvant chemotherapy might be the only solution for a proportion of patients with tumors that are unresectable at diagnosis, emergence of strategies that use risk group-directed therapy became an integral part in the management of oncological malignancies. Tumor histopathological change post neoadjuvant chemotherapy is one of the most important predictors of management outcome and is being used in many chemotherapy protocols as an essential determinant of the most suitable postoperative chemotherapy regimen. Bone tumors are the classic models of this approach; however, other childhood solid tumors show significant variations in outcome as a result of tumor histopathological response to neoadjuvant chemotherapy. The aim of this review is therefore to summarize the significance of histopathological responses seen after neoadjuvant chemotherapy in childhood solid tumors. Moreover, it suggests that the effect on tumor histopathology through modifying neoadjuvant chemotherapy and, on the other hand, toxicities from intensifying adjuvant chemotherapy might either necessitate the change of a number of arm groups in different protocol regimens or include newer chemotherapeutic agents adjuvantly for better outcome and lesser toxicities in poor tumor histopathological responders.

BackgroundPosterior reversible encephalopathy syndrome is a neurotoxic condition that occurs as a result of the failure of posterior circulatory autoregulation in response to acute changes in blood pressure. Overperfusion with resultant disruption of the blood-brain barrier results in vasogenic edema, but not infarction. Posterior reversible encephalopathy syndrome can be the presenting feature of postinfectious glomerulonephritis, which has been reported in approximately 5% of hospitalized children, and it has been reported in very few cases of adult patients with sickle cell anemia. We report a very rare case of posterior reversible encephalopathy syndrome that occurred in a child with sickle cell anemia. This presentation should be differentiated from other neurologic manifestations that occur in patients with sickle cell anemia, because management is totally different.Case presentationWe report what is to our knowledge the first reported case of a 9-year-old Saudi girl with sickle cell anemia who developed posterior reversible encephalopathy syndrome secondary to asymptomatic poststreptococcal glomerulonephritis. This occurred after full recovery from acute chest syndrome and severe vaso-occlusive crisis.ConclusionsThe purpose of this report is to emphasize that all efforts should be made to explore the causes of different neurologic manifestations that occur in patients with sickle cell anemia, because this will require different pathways of management.

The Sour Cluster is located in the south of the Sultanate of Oman. Since the first oil discovery in 1997, a successful exploration drilling campaign was carried out in the Cluster, resulting in the discovery of several carbonate stringer oil and gas reservoirs. Approximately half the gas volumes are contained in a gas condensate field. This field will be developed along with the other oil reservoirs in the cluster and will export gas to market as well as provide a source of make-up gas for the miscible gas injection operations.In phase 1 of the development (normal depletion), the wells were routed to the existing station-B via the Early Development Facility (EDF). These facilities consisted of a number of remote manifolds, a 70 km multiphase pipeline to station-B and a new oil and gas compression train at station-B. Whilst the field was depleted via station-B, design and construction of the new plant (phase 2) progressed.First production from phase 2 commenced 10 April, 2012, some 3.5 years after the target first oil date. Despite the delayed start, this first oil milestone is considered a commendable achievement given the significant challenges faced by the project team during the execution phase. Building a facility to handle the extreme mixture of high pressure, sour corrosive fluids and gas contained within the sour reservoirs is a technical step-out for PDO, let alone the oil industry in general.The establishment of the new Production Station (Station-H) now provides the infrastructure for long term development of the area and a number of follow-on projects which will make use of these facilities are either already in operation (Phase 3) or in execution(Integrated Phase 4). Learning from phase 2 has been taken onboard in the design of these follow-on projects and the area will deliver robust value to PDO / Oman for generations to come. This paper will outline some of the key challenges that were overcome by the design and project execution teams on the phase 2 project and how lessons learned were taken onboard to facilitate project delivery of the extended larger MGI development for follow-up phases and in similarly challenging projects in PDO.

We report a rare case of myelodysplastic syndrome that presented early as amegakaryocytic thrombocytopenia in a collodion baby, which is a rare congenital disorder characterized by thick, taut membrane resembling oiled parchment or collodion, which is subsequently shed. To our knowledge, this is the first reported case of a collodion baby who presented with amegakaryocytic thrombocytopenia and who has a significant family history of the same condition. We document the rarity of this possible association and also the need for further study to establish whether a causal relationship exists.